medigraphic.com
ISSN 2078-7170 (Electronic)

2011, Number 4

<< Back Next >>

CorSalud 2011; 3 (4)

Behavior of acute heart failure in the Intensive Care Unit of Riberalta, Bolivia

Rodríguez GF, Alonso PM, Machín CWJ, Ramírez MM, González FV

Language: Spanish
References: 53
Page: 198-208
PDF size: 168.13 Kb.


ABSTRACT

Introduction and Objectives: Heart failure is a major cause of admission to intensive care units. The objective of this research was to describe the behavior of acute heart failure in the Intensive Care Unit of Riberalta, Bolivia. Method: A cross sectional study was conducted with 141 patients who were admitted with this diagnosis in the period June 2006-August 2008. Results: The most represented age group was 60 years and over (37.6%), while acute coronary syndrome was the main precipitating factor (29.8%) and cardiomyopathy the fundamental causal factor (36.2%). The most common clinical presentation was acute decompensation (39.7%) and the highest percentage of patients had a hospital stay of 7 or more days (64.5%), in which heart failure was more representative (66%) and living discharged patients were more prevalent (80.9%). The largest proportion of patients received potassium-sparing diuretics (90.5%), beta blockers (96.9%) or the association of inhibitors of angiotensin converting enzyme and antagonists of angiotensin II receptors with one of them (95.2 and 94.1% respectively) . The risk of dying was 54 times higher in patients requiring vasoactive drugs, and 9 times in those using digitalis. Conclusions: Female sex predominated with 60 and more years. Cardiogenic shock, acute pulmonary edema and the number of admissions were the main determinants of mortality. The use of hormone-blocking drugs was favorably associated with survival; the opposite happened with the inotropes.


REFERENCES

  1. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993;22(4 Suppl A):6A-13A.

  2. Arnold JM, Gula LJ. The art and science of heart failure: predicting the unpredictable. J Am Coll Cardiol. 2010;55(17):1811-3.

  3. Poole-Wilson PA. History, definition and classification of heart failure. Heart Failure 1. New York: Churchill Livingstone; 2007. p. 269-77.

  4. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112(12):154-235.

  5. Heart Failure Society of America. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006;12(1):10-38.

  6. NICE. Chronic Heart Failure. National Clinical Guidelines for Diagnosis and Management in Primary and Secondary Care. The National Collaborating Centre for Chronic Conditions. London: NICE; 2005.

  7. Packer, M. Survival in patients with chronic heart failure and its potential modification by drug therapy. In: Cohn JN, editor. Drug Treatment of Heart Failure, 2nd ed. Secaucus: ATC International; 1998. p. 273.

  8. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet. 1997; 350 (9089):1417-24.

  9. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver, et al. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol. 2002;39 (1):60-9.

  10. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, et al. The Euro Heart Failure survey programmea survey on the quality of care among patients with heart failure in Europe. Part 1: Patient characteristics and diagnosis. Euro Heart J. 2003; 24(5):442-63.

  11. Kannel WB. Epidemiologic aspects of heart failure. In: Weber KT, editor. Heart Failure: Current Concepts and Management. Cardiology Clinics Series 7/1. Philadelphia: Saunders Co; 2004.

  12. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure, the Framingham Study. N Engl J Med. 1971;285 (26):1441-6.

  13. Francino A, Navarro-López F. Pronóstico del síndrome de la insuficiencia cardíaca. Rev Esp Cardiol. 2002;50 Suppl 3:11-17.

  14. Saavedra Suárez F; Organización Panamericana de la Salud-Bolivia. Región neumonía y gastroenteritis: Chagas y cáncer son principales causas de muerte en Chuquisaca [Internet]. 2007 [citado 4 Ago 2008]. Disponible en: http://www.ops.org.bo/servicios/?DB=B&S11=13083 &SE=SN

  15. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR. Congestive heart failure in the community. A study of all the incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998;98:2282-9.

  16. Riesgo A, Herrero P, Llorens P, Jacob J, Martin- Sanchez FJ, Bragulat E, et al. Influence of patient's sex in the form of presentation and the management of acute heart failure in Spanish emergency rooms. Med Clin (Barc). 2010;134(15):671-7.

  17. Macabasco-O'Connell A, Crawford MH, Stotts N. Gender and racial differences in psychosocial factors of low-income patients with heart failure. Heart Lung. 2010;39(1):2-11.

  18. Gonçalvesová E, Varga I, Lesný P, Líska B, Luknár M, Solík P. Characteristics and the prognosis of patients with acute heart failure in current clinical practice. Vnitr Lek. 2010;56(8):845-53.

  19. Domínguez JP, Harriague CM, García-Rojas I, González G, Aparicio T, González-Reyes A. Insuficiencia cardiaca aguda en pacientes de 70 años o más: factores precipitantes de descompensación. Rev Clin Esp. 2010;210(10):497-504.

  20. Braunwald E (chair): Report of the Task Force on Research in Heart Failure. Bethesda, MD, National Heart, Lung and Blood Institute; 1999.

  21. Nieminen MS, Böhm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Euro Heart J. 2005;26(4):384-416.

  22. Dickstein K. Guía de práctica clínica de la Sociedad Europea de Cardiología (ESC) para el diagnóstico y tratamiento de la insuficiencia cardíaca aguda y crónica. Rev Esp Cardiol. 2008;61(12):1329.e1-70.

  23. Fuster V, Rydén L, Cannom D, Crijns H, Curtis A, Ellenbogen K. ACC/AHA/ESC: Guía de práctica clínica 2006 para el manejo del paciente con fibrilación auricular. Rev Esp Cardiol. 2006;59(12):1329. e1-64.

  24. Nieminen MS, Böhm Ml, Cowie M, Drexler H, Filippatos G, Jondeau G, et al. Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la insuficiencia cardíaca aguda. Rev Esp Cardiol. 2005; 58(4):389-429.

  25. Albert K, Sherman B, Backus B. How length of stay for congestive heart failure patients was reduced through six sigma methodology and physician leadership. Am J Med Qual. 2010;25(5):392-7.

  26. de Lissovoy G, Fraeman K, Teerlink JR, Mullahy J, Salon J, Sterz R, et al. Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study. Eur J Health Econ. 2010;11(2): 185-93.

  27. Departamento de Estadísticas. Gerencia de REDES Riberalta; Junio 2007.

  28. Pecini R, Moller DV, Torp-Pedersen C, Hassager C, Kober L. Heart failure etiology impacts survival of patients with heart failure. Int J Cardiol. 2011; 149(2):211-5.

  29. López Castro J, Almazan Ortega R, Pérez De Juan Romero M, González Juanatey JR. Factores pronósticos de mortalidad en la insuficiencia cardíaca en una cohorte de España. Estudio EPICOUR. Rev Clin Esp. 2010;210(9):438-47.

  30. Ramani GV, Uber PA, Mehra MR. Chronic heart failure: contemporary diagnosis and management. Mayo Clin Proc. 2010;85(2):180-95.

  31. ESC Heart Failure Association Congress, 29 May to 1 June 2010, Berlin. Eur Heart J. 2010;31(15): 1811-2.

  32. Banović M, Vasiljević-Pokrajcić Z, Vijisić-Tesić B, Stanković S, Nedeljković I, Petrović O, et al. Are the novo acute heart failure and acutely worsened chronic heart failure two subgroups of the same syndrome?. Srp Arh Celok Lek. 2010;138(3-4):162- 9.

  33. Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, et al. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2010;12(10): 1076-84.

  34. Filippatos G, Zannad F. An introduction to acute heart failure syndromes: definition and classification. Heart Fail Rev. 2007;12:87-90.

  35. The Criteria Committee of the New York Heart Association: Nomenclature and Criteria for Diagnosis. 9th ed. Boston: Little Brown; 2004.

  36. Velavan P, Khan NK, Goode K, Rigby AS, Loh PH, Komajda M, et al. Predictors of short term mortality in heart failure - insights from the Euro Heart Failure survey. Int J Cardiol. 2010;138(1):63-9.

  37. Zuily S, Jourdain P, Decup D, Agrinier N, Loiret J, Groshens S, et al. Impact of heart failure management unit on heart failure-related readmission rate and mortality. Arch Cardiovasc Dis. 2010;103(2):90- 6.

  38. Bueno H, Ross JS, Wang Y, Chen J, Vidán MT, Normand SL, et al. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. JAMA. 2010; 303(21):2141-7.

  39. Gordon HS, Nowlin PR, Maynard D, Berbaum ML, Deswal A. Mortality after hospitalization for heart failure in blacks compared to whites. Am J Cardiol. 2010;105(5):694-700.

  40. Patterson ME, Hernández AF, Hammill BG, Schulman KA. Process of care performance measures and long-term outcomes in patients hospitalized with heart failure. Med Care. 2010;48(3):210-6.

  41. Bernheim SM, Grady JN, Lin Z, Wang Y, Savage SV, Bhat KR, et al. National patterns of riskstandardized mortality and readmission for acute myocardial infarction and heart failure. Update on publicly reported outcomes measures based on the 2010 release. Circ Cardiovasc Qual Outcomes. 2010;3(5):459-67.

  42. Holland R, Rechel B, Stepien K, Harvey I, Brooksby I. Patients' self-assessed functional status in heart failure by New York Heart Association class: a prognostic predictor of hospitalizations, quality of life and death. J Card Fail. 2010;16(2):150-6.

  43. O'Connor CM, Fiuzat M. Is rehospitalization after heart failure admission a marker of poor quality? Time for re-evaluation. J Am Coll Cardiol. 2010; 56(5):369-71.

  44. Teng TH, Finn J, Hobbs M, Hung J. Heart failure: incidence, case fatality, and hospitalization rates in Western Australia between 1990 and 2005. Circ Heart Fail. 2010;3(2):236-43.

  45. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized ALdactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-17.

  46. The Cardiac Insufficiency Bisoprolol Study II (CIBISII): a randomised trial. Lancet. 1999;353 (9146):9- 13.

  47. Effect of CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353 (9169):2001-7.

  48. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106 (17):2194-9.

  49. Richardson DM, Bain KT, Diamond JJ, Novielli KD, Lee SP, Goldfarb NI. Effectiveness of guidelinerecommended cardiac drugs for reducing mortality in the elderly medicare heart failure population: a retrospective, survey-weighted, cohort analysis. Drugs Aging. 2010;27(10):845-54.

  50. Buerke M, Lemm H, Russ M, Schlitt A, Werdan K. [Therapeutic strategies in acute decompensated heart failure and cardiogenic shock]. Internist (Berl). 2010;51(8):963-74.

  51. Butler J, Anand IS, Kuskowski MA, Rector T, Carson P, Cohn JN. Digoxin Use and Heart Failure Outcomes: Results from the Valsartan Heart Failure Trial (Val-HeFT). Congest Heart Fail. 2010;16(5): 191-5.

  52. Campia U, Nodari S, Gheorghiade M. Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events? Curr Heart Fail Rep. 2010;7(3): 100-9.

  53. Toma M, Starling RC. Inotropic therapy for endstage heart failure patients. Curr Treat Options Cardiovasc Med. 2010;12(5):409-19.




2020     |     www.medigraphic.com